PBYI Q3 2020 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M-10.0% YoY

Gross Profit

$41M80.4% margin

Operating Income

-$12M-23.9% margin

Net Income

-$31M-62.0% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-28.1%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$2M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$262M

Total Liabilities

$262M

Stockholders' Equity

-$453,000

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$56M	-10.0%
Gross Profit	$41M	$47M	-13.2%
Operating Income	-$12M	-$14M	+15.8%
Net Income	-$31M	-$17M	-86.2%

Revenue Segments

License

$3M66%

Royalty

$1M34%